Morguet A J, Munz D L, Kreuzer H, Emrich D
Department of Cardiology and Pulmonology, Georg-August University, Göttingen, West Germany.
Nucl Med Commun. 1990 Nov;11(11):727-35. doi: 10.1097/00006231-199011000-00002.
Monoclonal 111In antimyosin Fab is a marker for myocytes which have lost their membrane integrity. Because of the slow blood pool clearance of the radiopharmaceutical, imaging is usually started 24-48 h after intravenous injection of 74 MBq of the tracer. This long postinjection interval restricts its utilization in the primary diagnosis of acute myocardial infarction. However, antimyosin may help to differentiate between necrotic and viable myocardium in the subacute stage of incomplete myocardial infarction. Serial endomyocardial biopsy for early detection of transplant rejection after heart transplantation may be partially replaced or supplemented by antimyosin scintigraphy. The compound may facilitate the diagnosis of myocarditis. Other potential indications may be prognostic assessment of dilated cardiomyopathy, monitoring cardiotoxic side-effects of chemotherapeutics, recognition of cardiac contusion as well as diagnosis of rhabdo- and leiomyosarcoma. In specific clinical situations 111In antimyosin Fab immunoscintigraphy may provide valuable diagnostic information.
单克隆¹¹¹铟抗肌凝蛋白Fab是细胞膜完整性丧失的心肌细胞的标志物。由于该放射性药物在血池中的清除缓慢，通常在静脉注射74MBq示踪剂后24 - 48小时开始成像。这种较长的注射后间隔限制了其在急性心肌梗死初步诊断中的应用。然而，抗肌凝蛋白可能有助于在不完全心肌梗死的亚急性期区分坏死心肌和存活心肌。心脏移植后用于早期检测移植排斥反应的系列心内膜心肌活检可能部分被抗肌凝蛋白闪烁扫描术替代或补充。该化合物可能有助于心肌炎的诊断。其他潜在的适应证可能包括扩张型心肌病的预后评估、监测化疗药物的心脏毒性副作用、识别心脏挫伤以及诊断横纹肌肉瘤和平滑肌肉瘤。在特定的临床情况下，¹¹¹铟抗肌凝蛋白Fab免疫闪烁扫描术可能提供有价值的诊断信息。
